Alkermes Plc Stock Price, News & Analysis

Alkermes (NASDAQ:ALKS) reported strong Q2 2025 financial results with total revenues of $390.7 million and GAAP net income of $87.1 million ($0.52 per share). The company demonstrated robust performance across its proprietary product portfolio, with LYBALVI reaching $84.3 million (18% growth), ARISTADA at $101.3 million (18% growth), and VIVITROL at $121.7 million (9% growth).

The company maintained a strong balance sheet with $1.05 billion in cash and investments as of June 30, 2025, up from $916.2 million in Q1. Additionally, Alkermes announced positive topline results from its Vibrance-1 phase 2 study of alixorexton in narcolepsy type 1, with detailed results to be presented at the upcoming World Sleep Congress.

The company reiterated its 2025 financial expectations and continues to demonstrate solid profitability with Adjusted EBITDA of $126.5 million for the quarter.

Alkermes (NASDAQ:ALKS) announced positive topline results from its Vibrance-1 Phase 2 study of alixorexton in patients with narcolepsy type 1 (NT1). The study met its primary endpoint, demonstrating statistically significant improvements in wakefulness across all tested doses (4mg, 6mg, and 8mg) compared to placebo.

The once-daily oral treatment showed clinically meaningful improvements in multiple areas: normalized wakefulness (MWT), reduced excessive daytime sleepiness (ESS), and improved patient-reported outcomes related to disease severity, fatigue, and cognition. The drug was generally well-tolerated, with no serious adverse events reported. Over 95% of participants continued into the seven-week open-label extension.

Based on these positive results, Alkermes plans to advance alixorexton to Phase 3 development for NT1. Detailed results will be presented at the World Sleep Congress in September 2025.

Alkermes (Nasdaq: ALKS), a global biopharmaceutical company focused on neuroscience, has scheduled its second quarter 2025 financial results conference call and webcast for July 29, 2025, at 8:00 a.m. ET.

The company specializes in developing treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Their pipeline includes clinical and preclinical candidates for neurological disorders such as narcolepsy and idiopathic hypersomnia. Alkermes maintains operations across Ireland, Massachusetts, and Ohio.

Alkermes plc (ALKS) announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, with management scheduled for a fireside chat presentation on June 9, 2025, at 10:00 a.m. EDT. The presentation will be accessible via webcast on the company's website under the Investors tab and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia, with operations across Ireland, Massachusetts, and Ohio.

Alkermes (ALKS) presented research findings from its psychiatry portfolio at multiple scientific conferences during spring 2025, focusing on its products LYBALVI and ARISTADA. Key presentations included analyses of LYBALVI's long-term safety study, examining lipid and glycemic profiles across patient subgroups over four years of treatment. The company shared data at major conferences including AAPP, NEI Spring Congress, ISPOR, APA, ASCP, and Psych Congress Elevate. Notable research included evaluations of LYBALVI's effects on schizophrenia symptoms and ARISTADA's efficacy in treating schizophrenia. The presentations demonstrated Alkermes' commitment to advancing psychiatric care and contributing to scientific evidence in treating schizophrenia and bipolar I disorder.

Alkermes (ALKS) will present new research on ALKS 2680, its novel oral orexin 2 receptor agonist, at SLEEP 2025 conference. The company will showcase eight posters and two oral presentations, including key findings from Phase 1 studies. ALKS 2680 is in phase 2 development for narcolepsy type 1, type 2, and idiopathic hypersomnia. Notable results include: - Statistically significant wake-associated qEEG profile vs placebo - Well-tolerated single doses with significant improvements in mean sleep latency - No cardiac safety concerns in healthy volunteers - Phase 1b study showed positive results across all tested doses The company is currently conducting Phase 2 Vibrance Studies and expects to share topline results from Vibrance-1 in early Q3. The presentations will also include research on the clinical, economic, and humanistic burden of narcolepsy, along with findings from patient interviews on idiopathic hypersomnia.

Alkermes (ALKS) reported Q1 2025 financial results with total revenues of $306.5 million and GAAP net income of $22.5 million ($0.13 per share). Key product revenues included VIVITROL at $101.0M, ARISTADA at $73.5M, and LYBALVI at $70.0M. LYBALVI showed strong growth with 23% revenue increase year-over-year. The company maintains a solid cash position of $916.2 million. Notably, Alkermes achieved a milestone in its ALKS 2680 program, completing enrollment in the Vibrance-1 phase 2 study for narcolepsy type 1, with topline results expected in early Q3. The company reiterated its 2025 financial guidance and continues to focus on strategic objectives in neuroscience, particularly the development of its orexin 2 receptor agonist program.

A new Harris Poll survey commissioned by Alkermes reveals insights into Alcohol Use Disorder (AUD) diagnosis and treatment among 300 adults aged 21-64. The survey highlights that:

47% of respondents were diagnosed following hospital/ER visits, while only 28% were identified through routine screenings. About 79% reported negative feelings upon diagnosis, including fear and shame. Among those treated, 70% are currently in treatment, utilizing various methods including prescription medication (50%), behavioral therapy (46%), and support groups (43%).

The survey found that healthcare providers play a crucial role, with 80% of respondents discussing prescription medications with their providers. Treatment shows positive impacts, with over 50% reporting improvements in physical health (61%), quality of life (60%), and relationships. Notably, 96% of current patients report satisfaction with their treatment.

Despite approximately 28 million U.S. adults having AUD, only about 2 million received treatment in the past year, highlighting a significant treatment gap.

Alkermes plc (Nasdaq: ALKS), a global biopharmaceutical company focused on neuroscience, has announced it will host a conference call and webcast presentation on Thursday, May 1, 2025, at 8:00 a.m. ET to discuss its first quarter financial results.

The presentation will be accessible through the Investors section of Alkermes' website, with dial-in options available for U.S. callers (+1 877 407 2988) and international callers (+1 201 389 0923). A replay will be available approximately two hours after the event.

Alkermes specializes in developing treatments for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, with ongoing research in neurological disorders including narcolepsy and idiopathic hypersomnia. The company maintains operations across Ireland, Massachusetts, and Ohio.